UNASSIGNED: The "sandwich" protocol, was first proposed by us and comprised of @entity4445 , @entity1891 , and @entity229 chemotherapy with radiotherapy, results in 2-year overall survival and progression-free survival rates that surpass traditional therapies for @entity1 with newly diagnosed, stage IE-IIE, nasal type, extranodal natural killer/ @entity784 . The results had been published by @entity5 . These @entity1 were followed up over a median period of 67  months, for which updates and the results of prognostic factors analyses are presented. The 5-year overall survival and progress-free survival rates were both 64%. The highest rates of @entity204 occurred during the first 6  months, and between the second and third year after enrollment. The initial therapeutic response (odds ratio  =  5.83; P  =  0.001) and B symptoms (odds ratio  =  6.13; P = 0.043) were significant prognostic factors for overall survival. However, the international prognostic index was not significant for progress-free survival and overall survival. There were no severe long-term side effects. These results indicate that the "sandwich" protocol may benefit the long-term survival of @entity1 with newly diagnosed stage IE-IIE, nasal type, extranodal natural killer/ @entity784 . However, additional studies with larger samples are required to confirm these results. This study is registered at www.Chictr.org (ChicTR-TNC-09000394).

Five-year analysis from phase 2 trial of "sandwich" chemoradiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/ XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity784 :: ('MESH:D016399', 'Disease') :: ['T-cell lymphoma'] @entity4445 :: ('80150', 'Gene') :: ['l-asparaginase'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity784 :: (MESH:D016399,Disease) :: ['T-cell lymphoma']
